

Adin Bohmiller
Freeport
LD 1847

As both a medical cannabis patient and a worker on a cannabis farm, I am writing in strong opposition to LD 1847.

The proposed expansion of testing, track-and-trace systems, and potency limits would significantly harm Maine's medical cannabis program. These burdensome regulations will increase costs, restrict access for patients, and threaten the viability of small, local caregivers and producers who are the backbone of our system.

We already maintain strict cleanliness, documentation, and quality standards. Adding unnecessary compliance layers—such as SKU-level testing and digital tracking—does not enhance safety. States with stricter testing have still seen contaminated products. These changes only benefit large corporations that can absorb the costs, while pushing out the community-based producers who built this industry responsibly.

Patients rely on trusted, local sources for safe, affordable medicine. Overregulation risks turning a successful, patient-centered program into a corporate-controlled system.

Cannabis should be treated like agriculture, not regulated into monopolies. I urge you to reject LD 1847 and protect the caregivers, patients, and small farms that make Maine's program work.